PLASMA MEASUREMENT OF D-DIMER AS DIAGNOSTIC-AID IN SUSPECTED VENOUS THROMBOEMBOLISM - AN OVERVIEW

Citation
H. Bounameaux et al., PLASMA MEASUREMENT OF D-DIMER AS DIAGNOSTIC-AID IN SUSPECTED VENOUS THROMBOEMBOLISM - AN OVERVIEW, Thrombosis and haemostasis, 71(1), 1994, pp. 1-6
Citations number
40
Categorie Soggetti
Hematology,"Cardiac & Cardiovascular System
Journal title
ISSN journal
03406245
Volume
71
Issue
1
Year of publication
1994
Pages
1 - 6
Database
ISI
SICI code
0340-6245(1994)71:1<1:PMODAD>2.0.ZU;2-Z
Abstract
This paper reviews the published experience with plasma measurement of D-dimer (DD), a specific degradation product of crosslinked fibrin, i n the diagnostic approach of venous thromboembolism (VTE). Pooling 11 studies (with weighting of the figures according to sample size) with a total of 1337 patients clinically suspected of deep venous thrombosi s (DVT) (prevalence of DVT 35%) disclosed an average weighted sensitiv ity of 96.8% (95% CI: 95.2-98.4) and specificity of 35.2% (95% CI: 32. 0-38.4) for the presence of DVT when the ELISA technique was used. In 908 patients suspected of pulmonary embolism (PE) from 9 trials (preva lence of PE 38%), the ELISA technique was associated with a weighted s ensitivity of 96.8% (95% CI: 95.0-98.6) and specificity of 45.1% (95% CI: 40.8-49.4) for the disease. Figures obtained with latex assays wer e definitely lower, precluding their use in the diagnostic approach of VTE. These results show that a low concentration of plasma DD measure d by the ELISA technique (usually less than 500 mug/l) might be used t o rule out VTE in clinically suspected patients. Increased plasma conc entrations are of no utility because of the low specificity of this te st result. The clinical usefulness of the DD ELISA test should now be assessed in management trials under routine conditions, in the frame o f clinical decision-making diagnostic processes. Lastly, the promising data obtained in a small number of asymptomatic, postoperative patien ts at risk of VTE deserve confirmation before the test can be recommen ded for initial screening in thromboprophylactic trials.